News

Spear is an international, multi-center, randomized, controlled, pivotal Phase III trial of picoplatin in patients with small cell lung cancer (SCLC) who were refractory to or progressed within

The suit, filed in US District Court for the Western District of Wisconsin, asserts that Affymetrix’s GeneChip HT array plate and GeneChip HT array plate scanner infringe upon

According to Merck, launches in other European countries are expected to take place in the coming months, once individual marketing authorizations are granted. Bioequivalent to the existing Glucophage

As of March 31, 2009, Alexza had consolidated cash, cash equivalents and marketable securities (including investments held by Symphony Allegro) of $40.7 million. “During the first four months

Looking forward for the full year 2009, the company anticipates that its reported revenues will be between a 1% decline and 1% growth over 2008. Excluding a 4%

Operating expenses decreased to $10.6 million for the first quarter of 2009 from $12.0 million for the first quarter of 2008, primarily as a result of a strategic

“We have a strong pipeline of new products in the FDA, additional new products coming through the development process, such as our troponin assay, but our marketing efforts

Cambrex, a provider of products and services to accelerate the development and commercialization of small molecule therapeutics, has reported increase in net income to $4.7m in the first

SOCMA and partners in federal government are working together to bring the latest information and guidance with regards to swine flu out break in the US and Mexico.